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Abstract 
Objectives: To assess the prevalence of combined hormonal contraceptives (CHC) in reproduc-
tive-aged women with systemic lupus erythematosus (SLE) with and without possible contrain-
dications, and determine factors associated with their use in the presence of possible contraindi-
cations. 
 Methods: This observational cohort study included premenopausal women aged 18-45 enrolled 
in the Systemic Lupus International Collaborating Clinics (SLICC) Registry ≤15 months of SLE 
onset, with annual assessments spanning 2000–2017.  World Health Organization Category 3 or 
4 contraindications to CHC [e.g. hypertension, antiphospholipid antibodies (aPL)] were assessed 
at each study visit. High disease activity (Systemic Lupus Erythematosus Disease Activity Index 
>12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication.  
Results: 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence 
of ≥1 possible contraindication to CHC. Women used CHC during 512 (8%) visits, of which 281 
(55%) took place in the setting of ≥1 possible contraindications.  The most frequently observed 
contraindications were aPL (52%), hypertension (34%), and migraine with aura (22%). Women 
with ≥1 contraindication were slightly less likely to be taking CHC (7% of visits, 95% CI 7-8) 
than women with no contraindications (9%, 95% CI 8-10).  
Conclusion: CHC use was low compared to general population estimates (>35%), and over half 
of CHC users had at least one possible contraindication. Many yet unmeasured factors, including 
patient preferences, may have contributed to these observations. Further work should also aim to 
clarify outcomes associated with this exposure. 
 
Keywords 
Systemic lupus erythematosus; antiphospholipid syndrome; contraception; epidemiology 
 
Key messages 
Women with SLE have frequent contraindications to Combined Hormonal Contraceptives  
Half of SLE women took Combined Hormonal Contraceptives in the presence of at least one 
possible contraindication 
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Most common contraindications to Combined Hormonal Contraceptives included antiphospho-
lipid antibodies, hypertension, and migraine with aura 
 
Introduction  
Systemic lupus erythematosus (SLE) is a chronic autoimmune rheumatic disease affect-
ing predominantly women of reproductive age. Appropriate contraceptive counselling and use 
have been identified as quality indicators in SLE [1, 2]. Combined hormonal contraceptives 
(CHC) are contraindicated in certain medical conditions, due to the excess risk of thromboem-
bolic events associated with estrogen exposure [3]. The World Health Organization (WHO) [4, 
5] and the United States Center for Disease Control and Prevention (CDC) [6] have published 
evidence-based medical eligibility criteria for CHC use.  A medical condition is assigned Cate-
gory 3 when ‘theoretical or proven risks usually outweigh advantages of use’ (e.g. controlled hy-
pertension, diabetes for ≥20 years) and assigned Category 4 when there is an ‘unacceptable 
health risk if used’ (e.g. stroke, migraine with aura) [4-6].  
A recent population-based study found that 13% of reproductive age women possessed 
WHO/CDC Category 3 or 4 contraindications to CHC, and despite this, 39% of this group were 
taking CHC [7].  Women with SLE may have a higher prevalence of medical contraindications 
to CHC compared to unaffected women, due to an increased prevalence of hypertension and 
thrombotic risk factors, including antiphospholipid antibodies (aPL) (i.e. lupus anticoagulant 
[LAC], anticardiolipin antibody [aCL], and anti-beta2 glycoprotein-1 antibodies [anti-ß2-GPI]) 
[8-10]. 
Two randomized controlled trials (RCTs) established that CHC use in SLE did not in-
crease flares [11] or global disease activity [12] at one year. However, the Safety of Estrogens in 
Lupus National Assessment (SELENA) trial excluded patients with high disease activity (Sys-
temic Lupus Erythematosus Disease Activity Index >12 or use of >0.5 mg/kg/day of prednisone) 
and medical contraindications to estrogen, as well as those without stable or improving disease 
activity over the last 3 months [11]. Sanchez-Guerrero et al.’s RCT included women with posi-
tive aCL and anti-ß2-GPI [12]. Although this trial was not powered to detect a difference in ad-
verse events in the subgroup of aPL-positive subjects who received CHC, all 4 subjects who de-
veloped thrombosis had positive aPL and had received hormonal contraception [12]. Based on 
the available data, a diagnosis of SLE with positive aPL or SLE with an unknown aPL status is a 
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Category 4 contraindication to CHC [4,6], and recent European League Against Rheumatism 
(EULAR) recommendations state that CHC be used in those with stable or inactive SLE and 
negative aPL [13].  
The prevalence of possible contraindications to CHC among SLE women of reproductive 
age is not known. Our objective was to characterize CHC use in a prospective cohort of women 
with incident SLE, determining the overall prevalence of possible contraindications to CHC as 
well as the proportion of CHC users with and without concurrent possible contraindications to 
CHC. We hypothesized that women with possible medical contraindications would be less likely 
to receive this form of contraception compared to those without contraindications.  
 
Methods 
Study design and participants 
The Systemic Lupus International Collaborating Clinics (SLICC) cohort is a multi-national in-
ception cohort for the study of SLE outcomes [14-17].  Patients meeting ≥4 American College of 
Rheumatology (ACR) classification criteria for SLE [18] were enrolled within 15 months of di-
agnosis. Disease activity, damage, serologic and other laboratory data, medication use, and other 
clinical outcomes were assessed prospectively at yearly intervals from 2000-2017 according to a 
standardized protocol [15]. Local institutional review board approval was obtained at each of the 
33 participating sites across 11 countries in North America, Europe, and Asia. This study com-
plies with the declaration of Helskinki, and was approved by the institutional review boards of 
the McGill University Research Ethics Boards, as well as of all SLICC participating sites, and a 
data use agreement was in place. Patient consent was obtained when patient enrolled in the 
SLICC cohort.  
The current study identified premenopausal women aged 18-45 from the SLICC cohort 
who could potentially be eligible to receive a contraceptive medication. Visits during which a 
subject was pregnant, and visits after which a subject had undergone menopause, hysterectomy 
and/or oophorectomy were excluded. 
We also excluded subjects who did not have any data on aPL status from the central la-
boratory at any visit. The first cohort visit with available aPL data was considered the first study 
visit (i.e. baseline), and all visits thereafter were included in the analyses.  
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Data sources and measurement 
Country of origin and race/ethnicity were evaluated at baseline, and the following varia-
bles were assessed in all subjects at baseline and each follow-up visit: age, education, disease 
duration, corticosteroid use and dosage, reproductive data including pregnancies and menopausal 
status, disease activity as measured by the Systemic Lupus Erythematosus Disease Activity In-
dex 2000 (SLEDAI-2K) [19] and disease damage as measured by the SLICC/ACR Damage In-
dex (SDI) [20]. Current hormonal contraceptive use and type was assessed at baseline and each 
follow-up visit by study investigators, using the standardized data collection form. The presence 
of the following Category-3 and Category-4 WHO medical contraindications to CHC [4]  was 
determined at baseline and each follow-up visit: hypertension (defined as the use of antihyper-
tensive therapy not prescribed for renal disease), current smoker aged ≥35, history of venous 
thromboembolism (anticoagulant use and/or presence of the ‘venous thrombosis’ item on the 
SDI), migraine with aura, cerebrovascular disease (current or past transient ischemic attack or 
ischemic stroke), ischemic heart disease (current or past myocardial infarction, angina, angio-
plasty, or coronary artery bypass grafting), peripheral vascular disease (current or past claudica-
tion), diabetes ≥20 years duration, history of breast cancer, valvular heart disease with pulmo-
nary hypertension (defined by the presence of these SDI items), and the presence of positive aPL 
(either LAC, aCL IgG, or anti-ß2-GPI IgM or IgG), defined as a single titer above the laboratory 
cutoff value. aPL were measured at a central laboratory at the Oklahoma Medical Research 
Foundation, United States, as previously described [21]. Migraine with aura was determined at 
each study visit from the linked registry of neuropsychiatric events within the SLICC inception 
cohort, ascertained through a detailed checklist [14]. High disease activity, defined as SLEDAI-
2K score >12 or use of prednisone equivalent of >0.5 mg/kg per day, was also evaluated as a rel-
ative contraindication to CHC, as these were exclusion criteria in the SELENA trial [11], and the 
EULAR guidelines recommend using CHC only in stable or inactive disease [13].  
 
Statistical analysis   
Characteristics were summarized in the form of means and standard deviations (SDs) for 
continuous variables and proportions for categorical variables. We calculated the proportion of 
women having ≥1 possible contraindication during the study period, as well as the proportion of 
visits where ≥1 possible contraindication was present.  The proportion of visits where CHC was 
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used with and without ≥1 possible contraindication was compared by calculating the 95% confi-
dence intervals (CI) for the difference in proportion for two independent samples. Among study 
visits where CHC was used in the presence of ≥1 possible contraindications, the frequency of 
each medical contraindication was determined. 
To assess potential predictors of possibly contraindicated CHC use, we performed a mul-
tivariate analysis using a generalized estimating equation (GEE) approach, with each subject 
serving as a cluster. The outcome was a visit in which the patient was taking CHC in the pres-
ence of ≥1 possible medical contraindications. These contraindications included venous throm-
boembolism, migraine with aura, cerebrovascular disease, ischemic heart disease, peripheral vas-
cular disease, diabetes >20 years, valvular heart disease with pulmonary hypertension, or history 
of breast cancer. In a given patient, once one of these contraindications was identified, they were 
considered to have this possible contraindication from that point forward. Additional possible 
contraindications, assessed in a time-dependent manner, included: smoking and age >35, high 
disease activity (SLEDAI-2K >12 or >0.5mg/kg/d prednisone dose), hypertension, and positive 
aPL. These items were allowed to change from one visit to the next. The baseline visit for the 
current study was considered the first visit at which an aPL value was measured. Missing aPL 
values at later visits were assigned the same value as the most recent preceding visit where a re-
sult was available. We included in our model education, race/ethnicity, and geographic region as 
potential predictors. All analyses were performed using STATA, version 15 (StataCorp, 2017, 
College Station TX). 
 
Results  
1224 SLE women contributing 7743 visits from 2000-2017 met inclusion criteria for the 
study, but 297 subjects (1241 visits) were excluded due to lack of any data on aPL status from 
the central laboratory and a further 187 visits were excluded as they took place prior to the first 
known aPL result. Thus 927 women were enrolled in the current study contributing 6315 eligible 
visits (Figure 1). Clinical and demographic characteristics of CHC users at baseline with and 
without ≥1 possible contraindications are listed in Table 1.  Mean age was 30.1 years (SD, 7.6) at 
study entry, 39% of subjects were Caucasian, and 65% had some post-secondary education. 
 742 (80%) subjects possessed ≥1 possible contraindication to CHC at some point during 
the study, while 3811 (60%) visits took place when a subject had ≥1 possible contraindication to 
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CHC. Excluding high disease activity as a contraindication, 706 (76%) women possessed ≥1 
possible contraindication to CHC at some point, representing 3675 (58%) visits with ≥ 1 WHO 
Category 3- or Category 4- contraindications to CHC.  
Eighty-two (9%) women were on CHC at baseline, while 17 (2%) were on progesterone-
only contraception.  Across all study visits, Caucasians had the greatest CHC use (332/2335, 
14%; 95% CI 13-16) with lower use among Hispanics (45/1209, 4%; 95% CI 3-5), Asians 
(64/1248, 5%; 95% CI 4-7), and Blacks, (25/973, 3%; 95% CI 2-4). Although Hispanic subjects 
had more visits with ≥1 possible contraindication to CHC compared to Caucasians [827/1209 
(68%, 95% CI 66-71) vs 1395/2335 (60%, 95% CI 58-62)], this was not observed for Asian sub-
jects [689/1248 (55%, 95% CI 52-58)] nor Black subjects [599/973 (62%, 95% CI 58-65)]. 
Among the 82 (9%) subjects on CHC at study entry, 45 (55%) possessed ≥ 1 possible 
contraindication to CHC, whereas among the 77 (8%) women who started CHC after their en-
rolment visit, 58 (75%) possessed ≥1 possible contraindication at some point after this visit. 
CHC was used at 512 (8%) visits overall, of which 281 (55%) took place in the presence of ≥1 
possible contraindication. Women with ≥1 possible contraindication were slightly less likely to 
be taking CHC [281/3811 visits (7%, 95% CI 7-8)] compared to women with no contraindica-
tions to CHC (231/2504 visits (9%, 95% CI 8-10), difference of proportion 2% (95% CI 0-3%).  
Among the 281 visits during which CHC was taken in the presence of ≥1 possible contra-
indication to CHC, 146 visits (52%) were in the presence of positive aPL. Other frequently ob-
served potential contraindications were hypertension (34%) and migraine with aura (22%) (Table 
2). Across all study visits, CHC was used in the presence of 2 possible contraindications at 70 
visits, and ≥3 simultaneous contraindications at 20 visits.  
In the multivariate analysis including all CHC-user visits (n=512), subjects from Europe 
were more likely to use CHC in the presence ≥1 possible contraindication [OR 2.8 (1.3 to 6.2)], 
while effect estimates for other variables were inconclusive (Table 3). We performed sensitivity 
analyses to ensure that this effect estimate was not driven by potential collinearity between coun-
try of origin and race/ethnicity (Table 4). The first model excluded race/ethnicity entirely, and 
the second excluded all Asian and Hispanic subjects (including but not limited to all subjects at 
the South Korean and Mexican study centres).  In both cases, the effect estimate for Europe was 
maintained.  
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Of the 103 (11%) women who took CHC in the presence of ≥1 possible contraindications 
at any visit, 24 (23%) were observed to stop the CHC by the following visit and 56 (54%) con-
tinued on CHC despite having a possible contraindication, while 23 (22%) stopped having the 
contraindication or did not have a further visit. Thirteen women had 3 visits and 17 had ≥ 4 con-
secutive visits while taking CHC with a contraindication.  
 
Discussion 
In this large international inception cohort, over half of SLE women possessed ≥1 possi-
ble contraindications to CHC, which is much greater than prevalence estimates in general popu-
lation samples (3% -18%) [7, 22, 23]. The high prevalence of possible contraindications to estro-
gen among SLE women reflects the fact that many are frequent co-morbidities and complications 
of SLE [9, 24, 25].  
Over half of CHC users had ≥1 possible contraindications to estrogen, with the most 
common being aPL and hypertension. Women who presented ≥1 possible contraindication were 
almost as likely to be taking CHC as those who did not have any contraindications. Lauring et al 
observed that, among a general population sample, women with contraindications and those 
without also took CHC with approximate equal frequency (39% vs 47%) [7]. In our study, 11% 
of SLE women took CHC in the presence of ≥1 possible contraindication at some point, which 
might suggest room for improvement in prescribing practices. However, the finding that very 
few subjects took CHC in the presence of 2 or 3 simultaneous contraindications, and that nearly 
a quarter of subjects taking CHC with a contraindication had stopped the CHC by the following 
year, is reassuring. The benefits of reliable contraception offered by CHC, in some patients (with 
or without intolerance to other contraceptive types), may outweigh the risk associated with the 
possible contraindication. For example, adverse pregnancy outcomes are increased among pa-
tients with active SLE [26] and nephritis [27], while teratogenic medications mandate the use of 
reliable contraception. 
We found a low prevalence of any hormonal contraceptive use in SLE women (11% at 
baseline) compared to general population estimates (28-46%) [7, 28] and other cohort studies of 
SLE women (18 - 24%) [2, 28, 29], although one earlier Finnish study found a similar preva-
lence to our study (6%) [30].  This may be due in part to an increased awareness of the potential 
for contraindications to CHC among providers and/or patients. Of note, progesterone-only con-
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traception and intra-uterine devices can serve as safer alternatives for patients unable to take 
CHC [4], and we observed a low frequency of progesterone-only contraceptive use (2%). Previ-
ous research has suggested a deficiency of contraceptive counselling in SLE women [2, 29, 31], 
and interdisciplinary collaboration may be helpful for counselling SLE women on contraceptive 
options. SLE women may be less sexually active than the general population, due to a variety of 
psychosocial and chronic disease factors [32], and request less contraception.  
The SLICC cohort provides a broad representation of SLE patients from varying socio-
demographic backgrounds and healthcare settings.  The prevalence of CHC use across different 
regions and ethnicities was variable, with ethnic minorities (Black, Asian, Hispanic) having low-
er frequency of CHC use than Caucasians, despite having a similar prevalence of possible con-
traindications to CHC. Although European subjects were more likely to take CHC in the pres-
ence of a possible contraindication in the multivariate analysis, heterogeneity in CHC use among 
individual European countries, and the low numbers of subjects in several centers makes general-
ization within this region difficult. These results should rather serve to highlight the need for cen-
tre-specific evaluation and optimization of contraceptive use among SLE patients.    
This study is the largest and only multi-centre assessment to date of CHC use in SLE 
women from the time of SLE onset. Furthermore, it is the first to systematically assess the preva-
lence of contraindications to CHC in SLE based on internationally established criteria [4]. A 
cross-sectional study of 206 SLE women noted that 4/15 subjects taking CHC had aPL or a his-
tory of thrombosis, but other possible medical contraindications were not assessed [2].  Our re-
search has identified a potential unmet need in this population, since 55% of CHC users pos-
sessed a possible medical contraindication. 
Our study has limitations. A Category 3 designation acknowledges that although the risks 
outweigh the benefit of CHC, it could be used if an alternative method was not available. There-
fore, some providers might have made an appropriate treatment decision, given the well-
established risks of pregnancy in some clinical situations [33, 34]. No information was available 
on contraceptive prescribers (specialty, clinic setting), or the patients’ role in the contraceptive 
choice. The treating rheumatologist may have not been involved in the decision-making process, 
stressing the need for more data on this issue.  Although hypertension, thrombosis, ischemic 
heart disease, stroke, and migraine with aura were included as contraindications in the first edi-
tion of the WHO medical eligibility criteria for contraceptive use in 1996 [5], the presence of a 
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positive aPL in SLE was added as a contraindication in the fourth edition (2009) [35], after co-
hort inception (2000). This may partly explain why aPL was a frequently observed contraindica-
tion among women taking CHC, although thrombogenic conditions were considered contraindi-
cations as early as 2004 [35]. We used aPL values generated in the central lab of one of the study 
investigators (JM), and these results were not fed back to the clinical centres. Though each centre 
presumably had done aPL testing of their patients for clinical reasons, the results could have 
been divergent (i.e. a test could have been negative at the local test centre and positive at the cen-
tral lab). Rightly or wrongly, the WHO/CDC recommendations do not specify a titre cutoff for 
aPL or the need for confirmatory testing and thus, all positive aPL (or unknown aPL status in an 
SLE patient) is considered a Category 4 contraindication [4, 6]. However, the risk of thrombosis 
among the different aPL is not uniform, the highest being with LAC [9], and varies according to 
aPL titres, with titers of > 40 U/mL aCL and anti-ß2-GPI required for the classification of an-
tiphospholipid syndrome [37]. Although there could be a reduced thrombotic risk after an initial-
ly positive aPL becomes negative [38, 39], the WHO [4], CDC [6], and EULAR recommenda-
tions [13] do not address this scenario in the management of CHC. If aPL had been considered a 
time-independent variable (always a contraindication even if future testing is negative), the prev-
alence of subjects with contraindications to CHC would have been even greater. No data was 
available on the type of CHC used, and while estrogen type may influence the cardiovascular 
safety of these medications [40], current CHC recommendations are uniform regardless of CHC 
type [4, 6]. 
Altogether, this study highlights the challenge of ensuring safe contraceptive use in SLE 
women of reproductive age. Medical contraindications to CHC are common. Even in the absence 
of apparent contraindications, hormonal contraception use is low. Health professionals (primary 
care physicians, gynaecologists, rheumatologists) should be aware that CHC should not be with-
held from SLE women, but that specific risk factors should be reviewed for each patient. Patients 
also should be educated regarding potential contraindications and risks/benefits of CHC. Physi-
cians’ and patients’ perspectives should be sought in order to optimize contraceptive counselling 
and appropriate contraceptive use in this population. Finally, adverse outcomes associated with 
CHC exposure in SLE women with possible contraindications is an important area of future re-
search. 
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Figure legend  
Figure 1: Flow diagram of study inclusion 
CHC: Combined Hormonal Contraceptive; SLICC: Systemic Lupus International Collaborating 
Clinics; aPL: antiphospholipid antibodies 
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Table 1. Baseline characteristics, overall and among CHC users with and without ≥1 possible 
contraindications to estrogen 
Characteristics  Total  
population 
(n=927) 
Combined Hormonal Contraceptive  
users (n=82) 
Without  
contraindication 
(n=37) 
With 1 or more 
contraindications 
(n=45) 
Age, mean (SD)  30.1 (7.6) 27.9 (6.8) 26.3 (5.7)
Education 
Years of post-secondary educa-
tion, mean (SD) 
 
Any post-secondary education, 
n (%) 
3.5 (2.1) 
 
 
607 (65) 
4.1 (2.4) 
 
 
28 (76) 
3.2 (1.7) 
 
 
29 (64) 
Ethnicity, n (%) 
Asian  
Black  
Caucasian  
Hispanic  
Indian subcontinent  
Other 
190 (20) 
157 (17) 
357 (39) 
140 (15) 
38 (4) 
45 (5) 
5 (14) 
3 (8) 
22 (59) 
2 (5) 
3 (8) 
2 (5) 
2 (4) 
3 (7) 
33 (73) 
5 (11) 
0 (0) 
2 (4) 
Country/continent, n (%) 
Canada 
United States 
Mexico 
Europe  
Asia 
231 (25) 
222 (24)  
111 (12) 
239 (26) 
124 (13) 
15 (41) 
8 (22) 
2 (5) 
11 (30) 
1 (3) 
17 (38) 
12 (27) 
4 (9) 
12 (27) 
0 (0) 
Disease duration, years, mean 
(SD) 
0.71 (0.74) 0.76 (0.86) 0.59 (0.72)
BMI, kg/m2, mean (SD)  24.5 (5.6) 23.8 (3.5) 24.6 (4.9)
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Table 2. Contraindications to CHC among SLE women using CHC with ≥1 possible contraindi-
cations 
Contraindications to CHC  Visits where CHC used with ≥1  
contraindication 
 (n= 281 visits) 
Antiphospholipid antibodies, n (%)* 
LAC, n(%) 
aCL, n(%) 
anti-B2-GPI n(%) 
146 (52) 
85 (30) 
42 (15) 
58 (21) 
Hypertension, n (%)† 96 (34) 
Migraine with aura, n (%) *  62 (22) 
History of venous thromboembolism, n (%)† 21 (7) 
SLEDAI score >12, n (%)  21 (7) 
Prednisone use ≥0.5 mg/kg/d, n (%)  17 (6) 
Ischemic stroke, n (%)*  13 (5) 
Smoker aged ≥35, n (%)†  10 (4) 
Valvular heart disease with pulmonary hyperten-
sion, n (%)* 
5 (2) 
Ischemic heart disease, n (%)*  4 (1) 
Diabetes ≥ 20 years, n (%)†  3 (1) 
History of breast cancer, n (%)*  1 (0) 
Peripheral vascular disease, n (%)*  1 (0) 
 
 
* WHO Grade 4 (unacceptable health risk, method not to be used) [4]† WHO Grade 3 (theoreti-
cal or proven risks usually outweigh the advantages) OR Grade 4 (unacceptable health risk, 
method not to be used) depending on clinical circumstances [4] CHC: Combined Hormonal Con-
traceptive; LAC: lupus anticoagulant; aCL: anticardiolipin antibody 
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Table 3. Univariate and multivariate logistic regression: factors associated with using CHC in 
the presence of ≥1 contraindications (n=512) 
Variable Univariate 
(OR, 95% CI) 
Multivariate  
 (OR, 95% CI) 
 
Post-secondary education 
 
0.69 (0.42,1.15) 
0.74 (0.44, 1.25) 
Race (vs Caucasian)   
Asian 0.89 (0.36,2.2) 0.96 (0.33, 2.75) 
Black 1.10 (0.38,3.23) 0.98 (0.32, 2.99) 
Hispanic 2.24 (0.76,6.61) 1.87 (0.12, 29.73) 
Indian subcontinent 0.58 (0.12,2.8) 0.37 (0.07, 1.97) 
Other 0.96 (0.29,3.19) 0.76 (0.22, 2.66) 
Region (vs. Canada)   
United States 1.30 (0.61,2.79) 1.33 (0.61, 2.89) 
Mexico 3.37 (1.02,11.18) 1.62 (0.08, 32.08) 
Europe 2.38 (1.12,5.05) 2.80 (1.26, 6.23) 
Asia 1.13 (0.19,6.59) 1.25 (0.17, 9.10) 
 
 
CHC: Combined Hormonal Contraceptive; OR: Odds ratio.  
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Table 4. Factors associated with CHC use in the presence of ≥1 contraindications: sensitivity 
analyses 
 
Variable  Model 1: original 
 
 
 
 
n=512 visits 
(OR, 95% CI)
Model 2: exclusion of 
race/ethnicity 
 
 
 
n=512 visits 
(OR, 95% CI)
Model 3: exclusion of po-
tential collinear variables 
(Asia, South Korea, His-
panic, Mexico) 
 
n=403 visits 
(OR, 95% CI)
Post-secondary education 0.74 (0.44,1.25) 0.73 (0.44,1.23) 0.81 (0.48,1.39)
Race (vs Caucasian) 
Asian 
Black 
Hispanic 
Indian subcontinent 
Other 
 
0.96 (0.33,2.75) 
0.98 (0.32,2.99) 
1.87 (0.12,29.73) 
0.37 (0.07,1.97) 
0.76 (0.22,2.66)
  
 
0.89 (0.28,2.83) 
 
0.29 (0.05,1.67) 
0.68 (0.18,2.53)
Region (vs Canada) 
United States 
Mexico 
Europe 
Asia 
 
1.33 (0.61,2.89) 
1.62 (0.08,32.08) 
2.8 (1.26,6.23) 
1.25 (0.17,9.1)
 
1.34 (0.62,2.87) 
3.1 (0.93,10.39) 
2.45 (1.15,5.21) 
1.22 (0.21,7.15)
 
1.67 (0.71,3.92) 
 
4.39 (1.77,10.86) 
 
 
CHC: Combined Hormonal Contraceptive; OR: Odds ratio.  
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